Xiaohui He
Hefei University of Technology(CN)ShanghaiTech University(CN)Jiangsu Institute of Parasitic Diseases(CN)Yangtze River Pharmaceutical Group (China)(CN)PLA Academy of Military Science(CN)Wuhan Sports University(CN)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Viral-associated cancers and disorders, Lung Cancer Treatments and Mutations, Chronic Lymphocytic Leukemia Research, Head and Neck Cancer Studies
Most-Cited Works
- → Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials(2018)500 cited
- → Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial(2021)439 cited
- → Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial(2021)392 cited
- → Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma(2005)357 cited
- → Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma(2023)208 cited
- → Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)